GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AC-201

Company
TWi Biotechnology, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01276106

    Study of AC-201 in Patients With Type 2 Diabetes Mellitus

    Not yet reported TWi Biotechnology, Inc. 259 participants Est. completion 2012-03 21 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01712204

    A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

    Not yet reported TWi Biotechnology, Inc. 82 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Gout Flares
    View official trial listing →
  • Completed NCT NCT02287818

    A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

    Not yet reported TWi Biotechnology, Inc. 127 participants Est. completion 2016-10-27 1 site Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT02994147

    A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

    Not yet reported TWi Biotechnology, Inc. 22 participants Est. completion 2019-10-02 1 site
    Other conditions: Hemophilic Arthropathy
    View official trial listing →
  • Completed NCT NCT06972888

    A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

    Not yet reported Accro Bioscience (Suzhou) Limited 145 participants Est. completion 2025-04-28 1 site Stand-alone
    Other conditions: Plaque Psoriasis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.